COMMENTS ON REVENUE GROUP BERHAD (0200) – UPDATE MAR 2021

 

FIGURE 1: REVENUE GROUP BERHAD LAST 2 YEARS SHARE PRICE TREND

 

**analysis based on 2020 annual report.

1.       GENERAL INTRO: REVENUES’s core business is providing payment solution platform.

 

2.       NOTABLE POINTS:

a.   REVENUE provides payment solutions to banks, nonbank institutions, physical store merchants, online store merchants and e-money payment scheme, including e-Wallets such as BOOST, Touch ‘n Go and GrabPay.

b.    In FY2020, the Group's overall revenue increased by RM19.53 million or 33.7% to RM77.51 compared to FY2019, its EDC terminals segments was its largest revenue contributor (60.9%), followed by electronic transaction processing segment (20.9%) and solution & services segment (18.2%). The higher revenue recorded in FY2020 was mainly attributed to the higher sales in the EDC terminal segment.

c.    However, its profit before tax (“PBT”) decreased by RM0.63 million to RM10.78 million in FY2020. The lower PBT margin was due to higher administrative expenses to support its business growth and a change in the GP margin contribution from the business segments.

 

3.       IS THIS COUNTER A STRONG GROWTH STOCK?        

a.    REVENUE RANGE (RM million): 77.5 million as reported in 2020 annual report, this is a low revenue company. Between year 2015-2020, the counter’s revenue has been on a significant rising trend. The Profit Before Tax (PBT) and Profit After Tax (PAT) are also on an overall rising trend. This shows that REVENUE is highly potential growth stock.

 

 b.   SHARE PRICE: from Jan 2018 to Jan 2021, share price ranged from RM1.30 to around RM1.50, since Feb 2021, share price has surged to around RM2.00.

c.     EARNING PER SHARE (EPS): earning per share in last 3 years was overall fluctuating, ranging from 1.85 to 4.61 sen.

 

 d.     PRICE TO EARNINGS (P/E) RATIO: N/A

e.      FUTURE POTENTIAL/PROSPECTS: share price expect to be stable in the next few years.

f.     CAPITAL EXPENDITURE (CAPEX): spending on purchase of new fixed assets and other investments amount to about RM 13.3 million, which is around 10.8% of total assets. This shows that the management is optimistic about the future prospect of the business, hence proceed to invest more in the future growth and expansion of the business.

 

4.       IS THIS A STRONG DIVIDEND STOCK?             

a.       DIVIDEND YIELD: in 2020 financial year, REVENUE did not declare a dividend payout to its shareholders.

b.      DIVIDEND PAYOUT RATIO: N/A

c.      CONSISTENCY: This counter’s dividend payout has been inconsistent (dividend paid to shareholders in 0 years out of 5 years) in the last five years.

 

5.       IS THE MANAGEMENT PERFORMANCE GOOD?

a.     RETURN ON EQUITY (ROE): in 2020 financial year, REVENUE reported a good return of shareholders’ equity, at 12.44%.

b.      COST-TO-INCOME RATIO: the cost-to-income ratio is 624%, which is in the medium range.

c.    DEBT-TO-EQUITY (GEARING) RATIO: Its gearing ratio is at 81%, whereby its debt level is less than its equity, resulting in a healthy balance sheet.

d.      CASH FLOW: cash flow is positive, at around RM 33.8 million, equivalent to RM 0.08 per share.

 

6.       OTHER INDICATORS:

a.    SUPPORT BY INSTITUTIONAL INVESTORS: this counter is well supported by institutional investors, there are 14 institutional investors at top 30 major shareholders list, including a few investment funds but not including insurance funds. Its major shareholders are Ng Chee Siong (13.86%), Ng Shih Chiow (14.03%) and Ng Shih Fang (13.9%).

Disclaimer: The content of the blog posts are for sharing purpose only. Readers are encouraged to carry out further research and analysis as well as follow up latest update information before making any investment decisions.

Feel free to “Like” or “Follow” my Facebook Page (大马股市分析 Malaysia Stock Analysis, https://www.facebook.com/%E5%A4%A7%E9%A9%AC%E8%82%A1%E5%B8%82%E5%88%86%E6%9E%90-Malaysia-Stock-Analysis-100684328044058 ) to receive latest updates on new articles.

No comments:

Post a Comment